LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.

US pharma major Eli Lilly’s orforglipron is emerging as a promising oral glucagon-like peptide (GLP)-1 therapy, with upcoming clinical milestones in obesity and diabetes set to shape its market ...

WeightWatchers has appointed Dr. Kim Boyd as chief medical officer and announced a new program focused on helping women ...

If you wish to turn $10,000 into $50,000 by 2035, you’re looking at a 400% gain over a 10-year horizon. In the past decade, ...

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS, ...

A collection of top researchers have made the case for a new way to understand and diagnose obesity beyond using BMI as a measure.

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...